Susoctocog Alfa

Summary

Susoctocog Alfa (CHEMBL5315075) is an approved protein (ATC B02BD14); indicated across 2 conditions including hemophilia a.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: B02BD14
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315075
Name	Susoctocog Alfa
Type	Protein
Max phase	4
ATC	B02BD14

Also known as: BAX-802, BAX802, Obizur, Susoctocog alfa, SUSOCTOCOG ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
hemophilia A	4	MONDO:0010602	MONDO:0010602

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06550882	Not specified	RECRUITING	A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
NCT02610127	Not specified	COMPLETED	Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
NCT03199794	Not specified	COMPLETED	Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).